chung88
commented
1 year ago | label 1 | property | cardinality | label 2 |
|---|---|---|---|
| blood to plasma ratio assay | has assay format | some | blood format |
| CYP reaction phenotyping | has assay format | some | S9 fraction format |
| S9 stability assay | has assay format | some | S9 fraction format |
| CYP chemical inhibition | has endpoint | some | fraction metabolised |
| CYP metabolite formation kinetics | has endpoint | some | fraction metabolised |
| CYP reaction phenotyping | has endpoint | some | fraction metabolised |
| hepatocyte relay assay | has endpoint | some | fraction metabolised |
| hepatocyte stability assay | has endpoint | some | CLint |
| microsomal stability assay | has endpoint | some | CLint |
| tissue binding assay | has endpoint | some | Partition Coefficient |
| BCRP inhibition assay | has assay design method | some | liquid chromatography |
| BCRP substrate assay | has assay design method | some | liquid chromatography |
| biliary excretion assay | has assay design method | some | liquid chromatography |
| blood to plasma ratio assay | has assay design method | some | liquid chromatography |
| CYP3A4 induction assay | has assay design method | some | liquid chromatography |
| hepatocyte low clearance relay assay | has assay design method | some | liquid chromatography |
| MAO reaction phenotyping assay | has assay design method | some | liquid chromatography |
| mass balance assay | has assay design method | some | liquid chromatography |
| MATE1 inhibition assay | has assay design method | some | liquid chromatography |
| MATE1 substrate assay | has assay design method | some | liquid chromatography |
| metabolite identification and profiling assay | has assay design method | some | liquid chromatography |
| human mammary epithelial cell permeability assay | has assay design method | some | liquid chromatography |
| monoamine oxidase inhibition assay | has assay design method | some | liquid chromatography |
| MRP2 inhibition assay | has assay design method | some | liquid chromatography |
| MRP2 substrate assay | has assay design method | some | liquid chromatography |
| OAT1 inhibition assay | has assay design method | some | liquid chromatography |
| OAT1 substrate assay | has assay design method | some | liquid chromatography |
| OAT2 inhibition assay | has assay design method | some | liquid chromatography |
| OAT2 substrate assay | has assay design method | some | liquid chromatography |
| OAT3 inhibition assay | has assay design method | some | liquid chromatography |
| OAT3 substrate assay | has assay design method | some | liquid chromatography |
| OATP1B1 inhibition assay | has assay design method | some | liquid chromatography |
| OATP1B1 substrate assay | has assay design method | some | liquid chromatography |
| OATP1B3 inhibition assay | has assay design method | some | liquid chromatography |
| OATP1B3 substrate assay | has assay design method | some | liquid chromatography |
| OATP2B1 substrate assay | has assay design method | some | liquid chromatography |
| OCT1 inhibition assay | has assay design method | some | liquid chromatography |
| OCT1 substrate assay | has assay design method | some | liquid chromatography |
| placental transfer assay | has assay design method | some | liquid chromatography |
| renal excretion assay | has assay design method | some | liquid chromatography |
| simulated intestinal fluid stability assay | has assay design method | some | liquid chromatography |
additional ADME axiom cardinality restrictions: has assay format, has endpoint, has assay design method